Want to see GB:SBTX full AI Analyst Report?
Top Page
SkinBioTherapeutics
(LSE:SBTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
12.50 p
▲(31.58% Upside)
Action:Reiterated
Date:07/23/26
The score is held back primarily by weak financial quality: despite strong revenue growth, profitability and cash flow are meaningfully negative. Technical indicators are relatively supportive with improving trend/momentum, but valuation remains constrained by losses (negative P/E) and no provided dividend yield.
Positive Factors
Strong revenue growth
Sustained double-digit revenue expansion indicates product-market fit and accelerating commercial traction. Over 2-6 months this supports scale economics, strengthens partner bargaining, and provides a foundation to invest in R&D and commercialization even if profitability lags.
Negative Factors
Ongoing unprofitability
Persistent negative net income and EBIT margins reduce internal funding for growth and force reliance on external capital. Without durable margin improvement, profitability risk can limit reinvestment, constrain strategic flexibility, and pressure valuation over multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Sustained double-digit revenue expansion indicates product-market fit and accelerating commercial traction. Over 2-6 months this supports scale economics, strengthens partner bargaining, and provides a foundation to invest in R&D and commercialization even if profitability lags.
Read all positive factors
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£24.62M
Dividend YieldN/A
Average Volume (3M)148.03K
Price to Earnings (P/E)―
Beta (1Y)-0.02
Revenue Growth95.16%
EPS Growth85.60%
CountryUK
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding259,168,670
10 Day Avg. Volume77,023
30 Day Avg. Volume148,028
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£8.20M
SkinBioTherapeutics Business Overview & Revenue Model
Company Description
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological p...
How the Company Makes Money
SkinBioTherapeutics primarily generates revenue by commercializing its skin-health technology and related ingredients via business-to-business arrangements. Key revenue streams include: (1) partnering with consumer brands or manufacturers to incor...
SkinBioTherapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.23M | 4.64M | 1.21M | 132.06K | 74.76K | 0.00 |
| Gross Profit | 2.95M | 2.71M | 683.04K | 85.19K | 45.34K | -5.05K |
| EBITDA | -99.28K | -196.54K | -2.72M | -2.96M | -2.95M | -1.49M |
| Net Income | -456.41K | -696.25K | -2.88M | -2.84M | -2.79M | -1.43M |
Balance Sheet | ||||||
| Total Assets | 9.60M | 12.13M | 5.22M | 2.59M | 3.08M | 5.73M |
| Cash, Cash Equivalents and Short-Term Investments | 3.12M | 4.78M | 800.90K | 1.31M | 1.80M | 4.61M |
| Total Debt | 939.16K | 993.47K | 818.74K | 100.65K | 127.86K | 139.85K |
| Total Liabilities | 1.63M | 2.71M | 2.25M | 599.34K | 609.61K | 519.67K |
| Stockholders Equity | 7.98M | 9.42M | 2.97M | 1.99M | 2.48M | 5.22M |
Cash Flow | ||||||
| Free Cash Flow | -2.05M | -1.30M | -2.92M | -2.81M | -2.77M | -1.67M |
| Operating Cash Flow | -2.02M | -1.30M | -2.73M | -2.65M | -2.67M | -1.56M |
| Investing Cash Flow | -177.13K | -1.62M | -2.30M | -165.28K | -96.81K | -112.31K |
| Financing Cash Flow | 4.09M | 6.90M | 4.51M | 2.32M | -35.12K | 4.12M |
SkinBioTherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £24.62M | -52.78 | -5.25% | ― | 95.16% | 85.60% | |
49 Neutral | £58.32M | -3.28 | -1411.54% | ― | 22.87% | 13.35% | |
46 Neutral | £5.94M | -1.52 | -52.92% | ― | 34.02% | -93.85% | |
40 Underperform | £24.96M | -11.08 | -353.21% | 17.86% | ― | 36.67% | |
40 Underperform | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% | |
39 Underperform | £29.26M | 44.03 | 14.26% | ― | ― | ― |
* Healthcare Sector Average
GB:SBTX
SkinBioTherapeutics
9.50
-6.00
-38.71%
GB:IMM
ImmuPharma
4.10
-6.70
-62.04%
GB:OPTI
OptiBiotix Health
5.75
-4.50
-43.90%
GB:AREC
Arecor Therapeutics PLC
77.50
5.00
6.90%
GB:APTA
Aptamer Group Plc
0.38
-0.73
-65.91%
GB:OBI
Ondine Biomedical, Inc.
11.25
-4.25
-27.42%
SkinBioTherapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
SkinBioTherapeutics to Outline FRP Findings and Outlook in Investor Presentation
Positive
Jun 29, 2026
SkinBioTherapeutics, a life sciences business listed on AIM and headquartered in Newcastle, develops evidence-based topical and oral products to support skin health, repair, well-being and beauty, underpinned by its SkinBiotix platform. The compan...
Business Operations and StrategyExecutive/Board Changes
SkinBioTherapeutics CFO to Depart as Group Installs Interim Finance Chief
Neutral
Jun 25, 2026
SkinBioTherapeutics, the AIM-listed skin health-focused life sciences group, has announced the resignation of Chief Financial Officer Emily Bertram, who will leave the company on 30 June 2026 after playing a key role in financial stewardship and g...
Business Operations and Strategy
SkinBioTherapeutics to Host Investor Presentation to Deepen Shareholder Engagement
Positive
Jun 23, 2026
SkinBioTherapeutics, a life sciences company specialising in evidence-based skin health solutions and oral supplements, leverages its SkinBiotix technology platform and contract manufacturing capabilities to support skin well-being, repair and bea...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
SkinBioTherapeutics Restates FY25 Results as CEO Probe Uncovers Fabricated Revenue
Negative
Jun 8, 2026
SkinBioTherapeutics reported unaudited half-year revenues to 31 December 2025 up 37.4% to £2.17m, driven by a full six-month contribution from Bio-Tech Solutions, stable Dermatonics sales, AxisBiotix product launches in over 180 Superdrug sto...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
SkinBioTherapeutics completes financial probe, delays results and appoints new auditor
Negative
May 28, 2026
SkinBioTherapeutics said its board has completed an investigation into its financial statements for the year to 30 June 2025 and expects to publish delayed interim HY26 results alongside restated, unaudited FY25 figures shortly. The company indica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.